Nearly 20% of patients with acute myeloid leukemia (AML) have an isocitrate dehydrogenase (IDH) mutation1,2

It's time to find them.

Know your patient’s IDH mutation status

Molecular Profiling can identify mutations associated with cancers, including IDH1 and IDH2 mutations.

Test your patients for IDH mutations

IDH Mutations in Acute Myeloid Leukemia (AML) patients

In AML, nearly 20% of patients have an isocitrate dehydrogenase (IDH) mutation1,2

IDH Mutations in glioma patients

IDH mutations occur frequently, in up to 70% of glioma patients4

IDH Mutations in cholangiocarcinoma patients

Up to 25% of patients with cholangiocarcinoma may have an IDH mutation3,4

  1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152.
  2. McKenney AS, Levine RL. Isocitrate dehydrogenase mutations in leukemia. J Clin Invest. 2013;123(9):3672-3677.
  3. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72-79.
  4. Grassian AR, Pagliarini R, Chiang DY. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2014;30(3):295-302.
  5. Yan H, Parsons W, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.

Keep Me Informed

Receive the latest information about IDH mutations and their role in cancer from Agios.
This information is intended for healthcare professionals.

*Required fields

I would like to receive future communications about IDH mutations from Agios focused on (select one or more):